References
- Onida F, Kantarjian H M, Smith T L, Bell G, Keating M J, Estey E H, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840–849
- Greenberg P, Cox C, LeBeau M M, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088
- Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D AG, Gralnick H R, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199
- Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D AG, Gralnick H R, et al. The chronic myeloid leukemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994; 87: 746–754
- Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
- Themeau T M, Grambusch P M, Fleming T R. Martingale-based residuals for survival models. Biometrika 1990; 77: 147–160
- Cox D R. Regression models and life tables (with discussion). J Stat Soc 1972; 34: 187–220
- Malcovati L, Della Porta M G, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594–7603
- Sokal J E. Prognosis in chronic myeloid leukaemia: biology of the disease vs. treatment. Baillieres Clin Haematol 1987; 1: 907–929
- Onida F, Ball G, Kantarjian H M, Smith T L, Glassman A, Albitar M, et al. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer 2002; 95: 1673–1684
- Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992; 6: 52–59
- Worsley A, Oscier D G, Stevens J, Darlow S, Figes A, Mufti G J. Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol 1988; 68: 17–21
- Molica S, Iannaccaro P, Albeti A. Chronic myelomonocytic leukemia: a test of a proposed staging system. Am J Hematol 1990; 35: 129–130
- Solal-Celigny P, Desaint B, Herrera A, Chastang C, Amar M, Vroclans M, et al. Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases. Blood 1984; 63: 634–638
- Germing U, Strupp C, Alvado M, Gattermann N. New prognostic parameters for chronic myelomonocytic leukemia?. Blood 2002; 100: 731–732
- Germing U, Kundgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 2004; 45: 1311–1318
- Bowen D T. Chronic myelomonocytic leukemia: lost in classification?. Hematol Oncol 2005; 23: 26–33
- Golub T R, Barker G F, Lowett M, Gilleland D G. Fusion of PDGF receptor β to a novel ets-like gene tel in chronic myelomonocytic leukemia with a t(5;12) chromosomal translocation. Cell 1994; 77: 307–316
- Gupta R, Knight C L, Bain B J. Receptor tyrosine kinase mutations in myeloid neoplasms (review). Br J Haematol 2002; 117: 489–508
- Pitini V, Arrigo C, Teti D, Barresi G, Righi M, Alo G. Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report. Haematologica 2003; 88: ECR18
- Levine R, Loriaux M, Huntly B JP, Loh M L, Beran M, Stoffregen E, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377–3379
- Jelinek J, Oki Y, Gharibzan V, Bueso-Ramos C, Prchal J T, Verstovsek S, et al. JAK2 mutation 1849G > T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005; 106: 3370–3373
- Steensma D P, Dewald G W, Lasha T L, Powell H L, McClure R F, Lenine R L, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and the myelodysplastic syndromes. Blood 2005; 106: 1207–1209